Oncopeptides (STO: ONCO)

Last close As at 28/03/2026

SEK1.38

−0.08 (−5.59%)

Market capitalisation

SEK569m

Oncopeptides is a Swedish biotech company developing peptide-drug conjugates for the treatment of hematological cancers, with a focus on relapsed or refractory multiple myeloma.

Latest Insights

Healthcare | Quickview

Oncopeptides — Targeted oncology with commercial momentum

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Sofia Heigis

    CEO

  • Henrik Bergentoft

    CFO